The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
Abstract
BACKGROUND AND OBJECTIVE: Many drugs, including proton pump inhibitors and certain antidepressants, are metabolized by the polymorphic cytochrome P450 (CYP) 2C19 enzyme. A significant portion of extensive metabolizers do not reach appropriate drug levels, and our objective was to investigate any genetic background. METHODS: The 5'-flanking region of the CYP2C19 gene from subjects with rapid omeprazole metabolism was sequenced, and CYP2C19 phenotype-genotype associations were analyzed in Swedish (n = 107) and Ethiopian (n = 126) extensive metabolizers. The relationship of the metabolic ratio of omeprazole (omeprazole/5-hydroxyomeprazole in plasma 3 hours after drug intake) with the area under the plasma concentration-time curve was used for prediction studies. Electrophoretic mobility shift assays were conducted by use of human nuclear protein extracts. Hepatic reporter vector transfections were carried out in CD1 mice. RESULTS: We identified a novel allele (CYP2C19*17) carrying -806C>T and -3402C>T, with a frequency of 18% in both Swedes and Ethiopians and 4% in Chinese subjects. In Swedes the metabolic ratio of omeprazole was higher in subjects homozygous for CYP2C19*1 (median, 0.50 [interquartile range, 0.37-0.73]) than in those homozygous for CYP2C19*17 (median, 0.25 [interquartile range, 0.15-0.33]) (P = .010). In Ethiopians a similar difference in the S/R-mephenytoin ratio was observed between individuals homozygous for CYP2C19*1 (median, 0.20 [interquartile range, 0.12-0.37]) and those homozygous for CYP2C19*17 (median, 0.05 [interquartile range, 0.03-0.06]) (P = .013). Electrophoretic mobility shift assays showed specific binding of human hepatic nuclear proteins to an element carrying -806T but not -806C. Reporter vector experiments showed an increased transcriptional activity of the CYP2C19*17 allele in vivo in mice. Predictions revealed that CYP2C19*17 homozygotes would attain 35% to 40% lower omeprazole area under the plasma concentration-time curve values than subjects homozygous for CYP2C19*1 taking standard doses of omeprazole. CONCLUSION: CYP2C19*17 is likely to cause therapeutic failures in drug treatment with, for example, proton pump inhibitors and antidepressants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
Desta, Z., Zhao, X., Shin, J.-G., & Flockhart, D. A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00002 · Cited by 942
Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001494 · Cited by 724
Furuta, T., Ohashi, K., Kamata, T., Takashima, M., Kosuge, K., Kawasaki, T., Hanai, H., Kubota, T., Ishizaki, T., & Kaneko, E. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-12-199812150-00006 · Cited by 335
genotype status and effect of omeprazole on intragastric pH in humans
FURUTA, T., OHASHI, K., KOSUGE, K., ZHAO, X., TAKASHIMA, M., KIMURA, M., NISHIMOTO, M., HANAI, H., KANEKO, E., & ISHIZAKI, T. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70075-5 · Cited by 272
Furuta, T. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113959 · Cited by 254
Shirai, N., Furuta, T., Moriyama, Y., Okochi, H., Kobayashi, K., Takashima, M., Xiao, F., Kosuge, K., Nakagawa, K., Hanai, H., et al. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.01108.x · Cited by 221
Chang, M., Dahl, M.-L., Tybring, G., Gotharson, E., & Bertilsson, L. (1995) · Pharmacogenetics · doi:10.1097/00008571-199512000-00004 · Cited by 203
Self-citationChang, M., Tybring, G., Dahl, M., Gotharson, E., Sagar, M., Seensalu, R., & Bertilsson, L. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04488.x · Cited by 184
Self-citationSmits, K. M., Smits, L. J. M., Schouten, J. S. A. G., Stelma, F. F., Nelemans, P., & Prins, M. H. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001488 · Cited by 177
CYP2C19 Polymorphism and Proton Pump Inhibitors
Klotz, U., Schwab, M., & Treiber, G. (2004) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1600-0773.2004.pto950102.x · Cited by 166
Ethnic Differences in Genetic Polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1
Ozawa, S., Soyama, A., Saeki, M., Fukushima-Uesaka, H., Itoda, M., Koyano, S., Sai, K., Ohno, Y., Saito, Y., & Sawada, J.-I. (2004) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.19.83 · Cited by 165
The karolinska cocktail for phenotyping of five human cytochrome P450 enzymes
Christensen, M. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00050-x · Cited by 157
Self-citationFuruta, T., Shirai, N., Watanabe, F., Honda, S., Takeuchi, K., Iida, T., Sato, Y., Kajimura, M., Futami, H., Takayanagi, S., et al. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127637 · Cited by 153
Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19
Wang, J., Liu, Z., Wang, W., Chen, X., Shu, Y., He, N., & Zhou, H. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.116513 · Cited by 147
Suzuki, E., Evans, T., Lowry, J. A., Truong, L. N., Bell, D. W., Testa, J. R., & Walsh, K. (1996) · Genomics · doi:10.1006/geno.1996.0630 · Cited by 147
Tamminga, W. J., Wemer, J., Oosterhuis, B., Wieling, J., Wilffert, B., de Leij, L. F. M. H., de Zeeuw, R. A., & Jonkman, J. H. G. (1999) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050615 · Cited by 144
Sertraline treatment of elderly patients with depression and cognitive impairment
Devanand, D. P., Pelton, G. H., Marston, K., Camacho, Y., Roose, S. P., Stern, Y., & Sackeïm, H. A. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.802 · Cited by 143
Pharmacogenomics of proton pump inhibitors
Furuta, T., Shirai, N., Sugimoto, M., Ohashi, K., & Ishizaki, T. (2004) · Pharmacogenomics · doi:10.1517/phgs.5.2.181.27483 · Cited by 139
Furuta, T., Shirai, N., Takashima, M., Fang, X., Hanai, H., Nakagawa, K., Sugimura, H., Ohashi, K., & Ishizaki, T. (2001) · Pharmacogenetics · doi:10.1097/00008571-200106000-00009 · Cited by 134
Identification and functional characterization of new potentially defective alleles of human CYP2C19
Blaisdell, J. A., Mohrenweiser, H. W., Jackson, J., Ferguson, S., Coulter, S. J., Chanas, B., Xi, T., Ghanayem, B. I., & Goldstein, J. A. (2002) · Pharmacogenetics · doi:10.1097/00008571-200212000-00004 · Cited by 132
Laine, K. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.108949 · Cited by 109
Hepatic Erythropoietin Gene Regulation by GATA-4
Dame, C., Sola, M. C., Lim, K.-C., Leach, K. M., Fandrey, J., Ma, Y., Knöpfle, G., Engel, J. D., & Bungert, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310404200 · Cited by 100
Schwab, M. G., Schaeffeler, E., Klotz, U. E., & Treiber, G. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.05.002 · Cited by 97
Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes
Herrlin, K., Yasui‐Furukori, N., Tybring, G., Widén, J., Gustafsson, L. L., & Bertilsson, L. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01874.x · Cited by 96
Self-citationAklillu, E., Herrlin, K., Gustafsson, L. L., Bertilsson, L., & Ingelman‐Sundberg, M. (2002) · Pharmacogenetics · doi:10.1097/00008571-200207000-00005 · Cited by 95
Self-citationS-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians
Persson, I., Aklillu, E., Rodrigues, F., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199612000-00005 · Cited by 90
Self-citationPHARMACOKINETICS OF CITALOPRAM IN RELATION TO GENETIC POLYMORPHISM OF CYP2C19
Yu, B., Chen, G., He, N., Ouyang, D., Chen, X., Liu, Z., & Zhou, H. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.10.1255 · Cited by 88
Yu, K. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.114231 · Cited by 87
Sagar, M., Tybring, G., Dahl, M., Bertilsson, L., & Seensalu, R. (2000) · Gastroenterology · doi:10.1053/gast.2000.16515 · Cited by 86
Self-citationTake, S., Mizuno, M., Ishiki, K., Nagahara, Y., Yoshida, T., Inaba, T., Yamamoto, K., Okada, H., Yokota, K., Oguma, K., et al. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00713-5 · Cited by 76
Yin, O. Q. P., Tomlinson, B., Chow, A. H. L., Waye, M. M. Y., & Chow, M. S. S. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004265702 · Cited by 51
Yokono, A., Morita, S., Someya, T., et al. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200112000-00002 · Cited by 42
Zhu, Q., Qian, B., & Levy, D. (2004) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/j.bbaexp.2004.01.002 · Cited by 24
Treatment-refractory depression: Definitions and characteristics
Berman, R. M., Narasimhan, M., & Charney, D. S. (1997) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1997)5:4<154::aid-da2>3.0.co;2-d
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“A further clinically relevant variant is the promoter variant –806C>T (*17) which appears to increase expression and activity toward mephenytoin and omeprazole by a still unclear mechanism (Sim et al., 2006).”
BackgroundGenetic Determinants of Response to Clopidogrel and Cardiovascular Events
Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Méneveau, N., Steg, P. G., Ferrières, J., Danchin, N., & Becquemont, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808227 · Cited by 1,728
Ingelman-Sundberg, M., Sim, S. C., Gomez, A., & Rodriguez-Antona, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.004 · Cited by 1,166
Self-citationHicks, J., Bishop, Jr., Sangkuhl, K., Müller, D., Ji, Y., Leckband, S., Leeder, J., Graham, R., Chiulli, D., LLerena, A., et al. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.147 · Cited by 998
Scott, S. A., Sangkuhl, K., Stein, C. M., Hulot, J.-S., Mega, J. L., Roden, D. M., Klein, T. E., Sabatine, M. S., Johnson, J. A., & Shuldiner, A. R. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.105 · Cited by 962
Metadata
- Authors
- SIM, S., RISINGER, C., DAHL, M., AKLILLU, E., CHRISTENSEN, M., BERTILSSON, L., & INGELMANSUNDBERG, M.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2006-01
- Volume
- 79
- Issue
- 1
- Pages
- 103-113
- ISSN
- 0009-9236 (ISSN-L)
- OpenAlex
- W2081558811
- Cited by
- 732
- References
- 35
- FWCI
- 34.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.